PAX8 Expression in Well-differentiated Pancreatic Endocrine Tumours

 

  Well differentiated neuroendocrine tumours: percentage of tumour nuclei positive for Pax8  
  5%-25% 26%-50% 51%-75% 76%-100%  
Primary Pancreatic 0/631 5/631 6/631 31/631
Ileal

0/311

Duodenal       5/51
Gastric       1/51
Appendiceal       4/191
Rectal   1/131 3/131 7/131
Pulmonary

0/201

Metastatic Pancreatic   1/181 1/181 7/181
Ileal

0/161

           

Pax8 negativity was more common in larger pancreatic neuroendocrine tumours and in primary tumours with liver metastases1.

Diagnostic utility

In metastatic well differentiated neuroendocrine tumour, Pax8 positivity may be useful as evidence of a pancreatic origin, in a panel along with PDX-1 and NESP-55.

References

1 Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010 May;34(5):723-9.

This page last revised 1.5.2010

©SMUHT/PW Bishop